Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Summary

The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.

Timeline

Start

2011-02-02

Primary completion

2017-05-31

Completion

2018-12-17

Outcome

Outcome not reported

Stopped: “For the last patient still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.”

Drugs

Indications